Extensively drug resistant tuberculosis
BMJ 2006; 333 doi: https://doi.org/10.1136/bmj.38971.587222.AB (Published 14 September 2006) Cite this as: BMJ 2006;333:559
- Stephen D Lawn (stevelawn@yahoo.co.uk), senior lecturer in infectious and tropical diseases,
- Robert Wilkinson, Wellcome Trust senior fellow in clinical tropical medicine
- Desmond Tutu HIV Centre, Institute of Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Anzio Road, Observatory 7925, Cape Town, South Africa
- Institute of Infectious Disease and Molecular Medicine, University of Cape Town
Tuberculosis outbreaks in the developed world are newsworthy.1 However, in the developing world, where deaths from tuberculosis are common, it takes something exceptional for an outbreak to attract much attention. In response to a recent report at the 16th international AIDS conference2 and to increasing South African media reports, the World Health Organization last week expressed concern about extensively drug resistant tuberculosis (also referred to as “XDR tuberculosis”).3
Among 536 culture confirmed cases of tuberculosis at a rural hospital in South Africa, 41% were multidrug resistant,2 defined as resistance to rifampicin and isoniazid (two key first line drugs). This is cause enough for concern as multidrug resistant tuberculosis has a worse outcome and its management is very difficult even in high resource settings.4 Even more alarming was that 53 (24%) of the isolates from multidrug resistant tuberculosis fulfilled the definition of extensively drug resistant tuberculosis2—namely, multidrug resistant tuberculosis that is also resistant to at least three of the six classes of second line agents. Such tuberculosis is virtually untreatable.
All patients in this outbreak who were tested were HIV infected, and 52 …